| Not Yet Recruiting | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma NCT07517705 | University of Nebraska | N/A |
| Not Yet Recruiting | Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymph NCT07476105 | Fondazione Italiana Linfomi - ETS | N/A |
| Not Yet Recruiting | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL NCT07528352 | University of Utah | Phase 1 |
| Not Yet Recruiting | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma NCT07502872 | Brown University | Phase 2 |
| Recruiting | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Sub NCT06863402 | Roswell Park Cancer Institute | Phase 2 |
| Not Yet Recruiting | Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission NCT07507318 | Rong Tao | Phase 2 |
| Recruiting | Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory D NCT07368270 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/ NCT07225439 | Paolo Caimi, MD | Phase 1 |
| Recruiting | Hyperfractionated Dual Equivalent Fractionated Radiation Therapy NCT06898905 | Yale University | N/A |
| Recruiting | An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma NCT07200375 | Hoffmann-La Roche | — |
| Not Yet Recruiting | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma NCT06665217 | Navy General Hospital, Beijing | Phase 2 |
| Not Yet Recruiting | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymp NCT07159906 | First Affiliated Hospital of Zhejiang University | Phase 1 / Phase 2 |
| Recruiting | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) NCT07059650 | Dizal Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Dif NCT06977711 | The University of Texas Health Science Center at San Antonio | Phase 1 |
| Not Yet Recruiting | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL NCT07012980 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ NCT06846463 | Virginia Commonwealth University | Phase 2 |
| Recruiting | Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patient NCT07070648 | Fudan University | — |
| Recruiting | Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxalipl NCT07001540 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers NCT06870487 | Pfizer | Phase 1 |
| Recruiting | Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large NCT06588205 | Fondazione Italiana Linfomi - ETS | — |
| Recruiting | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL NCT06768905 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Recruiting | A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma NCT06929624 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma NCT06829771 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL NCT06921044 | Xiaohui He | Phase 2 |
| Not Yet Recruiting | Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia NCT06323447 | Leuko Labs, Inc. | — |
| Recruiting | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL NCT06803693 | Ruijin Hospital | Phase 2 |
| Recruiting | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follic NCT06830759 | AbbVie | — |
| Recruiting | Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma NCT06830031 | Shanghai Exuma Biotechnology Ltd. | Phase 1 |
| Recruiting | Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment NCT06784167 | OHSU Knight Cancer Institute | — |
| Recruiting | Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesion NCT07198230 | Ting YANG | — |
| Recruiting | Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma NCT07188077 | Ting YANG | — |
| Recruiting | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies NCT05990465 | Medical College of Wisconsin | Phase 1 |
| Recruiting | CHiR Therapy for Elderly DLBCL Intolerant to Chemo NCT06764017 | First Affiliated Hospital of Ningbo University | Phase 2 |
| Recruiting | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubic NCT06717347 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Tra NCT06687772 | Washington University School of Medicine | Phase 2 |
| Recruiting | Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy NCT06758037 | First Affiliated Hospital of Ningbo University | Phase 2 |
| Recruiting | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL NCT06760039 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735 | British Columbia Cancer Agency | Phase 1 |
| Not Yet Recruiting | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL NCT06441097 | Ruijin Hospital | Phase 2 |
| Recruiting | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma NCT06736613 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL NCT06693830 | Hua-Jay J Cherng, MD | N/A |
| Active Not Recruiting | Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell NCT06552572 | Samsung Medical Center | Phase 2 |
| Recruiting | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cel NCT07254754 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Not Yet Recruiting | Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission NCT06669143 | Ruijin Hospital | Phase 2 |
| Not Yet Recruiting | Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive NCT06652139 | Ruijin Hospital | Phase 2 |
| Recruiting | Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnose NCT07072208 | The First Affiliated Hospital of Soochow University | N/A |
| Recruiting | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL NCT06651853 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy NCT06589089 | Ruijin Hospital | Phase 2 |
| Not Yet Recruiting | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated NCT06516978 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin NCT06813573 | Gustave Roussy, Cancer Campus, Grand Paris | N/A |
| Recruiting | Pola-ZR2P in Previously Untreated DLBCL NCT06664411 | Navy General Hospital, Beijing | Phase 2 |
| Recruiting | Emapalumab Prevention of CAR-T Cell Associated Toxicities NCT06550141 | Marcela V. Maus, M.D.,Ph.D. | Phase 2 |
| Not Yet Recruiting | A Real-World Study on Extranodal Lymphoma NCT06573099 | Ruijin Hospital | — |
| Recruiting | Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL NCT06503263 | Navy General Hospital, Beijing | Phase 2 |
| Withdrawn | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL NCT06290622 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or NCT06395103 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) I NCT06508658 | Genmab | Phase 3 |
| Recruiting | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients NCT06530511 | Affiliated Hospital of Nantong University | Phase 2 |
| Recruiting | Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) NCT06517511 | Sun Yat-sen University | Phase 2 |
| Recruiting | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-c NCT06522555 | Ruijin Hospital | Phase 3 |
| Recruiting | PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma NCT06755775 | Ruijin Hospital | — |
| Recruiting | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Ly NCT06517004 | Fudan University | Phase 1 |
| Recruiting | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL NCT05952024 | AstraZeneca | Phase 2 |
| Recruiting | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High NCT06249191 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma NCT06594640 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatmen NCT06451497 | Zumutor Biologics Inc. | Phase 1 |
| Recruiting | Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? NCT06352242 | University Hospital, Montpellier | N/A |
| Recruiting | Characterization and Clinical Impact of the Gut Microbiota in Lymphoma NCT06161896 | Lars Møller Pedersen | — |
| Unknown | Preliminary Assessment of [18F]BL40 in PET/CT Scans NCT06224309 | British Columbia Cancer Agency | — |
| Not Yet Recruiting | Maintenance Hormonal Therapy and DLBCL NCT06355401 | Sohag University | Phase 2 / Phase 3 |
| Active Not Recruiting | DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) NCT06539195 | Dizal Pharmaceuticals | Phase 2 |
| Recruiting | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen R NCT05887167 | Joshua Sasine, MD, PhD | Phase 1 |
| Recruiting | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refract NCT06227026 | University of Utah | Phase 1 |
| Recruiting | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. NCT06244368 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Completed | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) NCT06004167 | Massachusetts General Hospital | N/A |
| Active Not Recruiting | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. NCT06424379 | Hospices Civils de Lyon | — |
| Unknown | CD30 Imaging in Diffuse Large B-cell Lymphoma NCT06186986 | University Medical Center Groningen | Phase 3 |
| Recruiting | Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T NCT06439173 | Instituto de Investigación Biomédica de Salamanca | — |
| Completed | Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy NCT06141772 | Centre Henri Becquerel | N/A |
| Recruiting | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies NCT05541341 | Novartis Pharmaceuticals | — |
| Recruiting | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical NCT06120166 | He Huang | EARLY_Phase 1 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Recruiting | Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients NCT06176729 | Yan Zhang, MD | Phase 2 |
| Not Yet Recruiting | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) NCT05923502 | Ruijin Hospital | — |
| Recruiting | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in NCT06022029 | OncoNano Medicine, Inc. | Phase 1 |
| Recruiting | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas NCT05934838 | Weill Medical College of Cornell University | Phase 1 |
| Recruiting | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas NCT05365659 | Iksuda Therapeutics Ltd. | Phase 1 |
| Not Yet Recruiting | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermedia NCT05990985 | The First Hospital of Jilin University | N/A |
| Not Yet Recruiting | Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomar NCT05834426 | Sociedad de Lucha Contra el Cáncer del Ecuador | — |
| Active Not Recruiting | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Giv NCT05896163 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or NCT05660395 | ADC Therapeutics S.A. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Ch NCT05954910 | Hoffmann-La Roche | — |
| Unknown | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma NCT06149169 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 2 |
| Terminated | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diff NCT05626322 | Pfizer | Phase 1 / Phase 2 |
| Unknown | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors NCT05887726 | Liaoning Cancer Hospital & Institute | Phase 2 |
| Recruiting | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem C NCT05432635 | City of Hope Medical Center | Phase 1 |
| Unknown | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma NCT05940064 | Peng Liu | Phase 2 |
| Unknown | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05940051 | Peng Liu | Phase 2 |
| Completed | Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL NCT05958134 | AstraZeneca | — |
| Unknown | Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lympho NCT05875428 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Unknown | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types NCT05907447 | Ruijin Hospital | — |
| Unknown | A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL NCT05883709 | Zhao Weili | — |
| Recruiting | Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or NCT06918912 | Istituto Clinico Humanitas | Phase 2 |
| Recruiting | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lym NCT05633615 | SWOG Cancer Research Network | Phase 2 |
| Unknown | A Combination Study of CAR-T Therapy in r/r B-NHL NCT05871684 | Ruijin Hospital | Phase 2 |
| Recruiting | Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma NCT05820841 | Universität des Saarlandes | Phase 3 |
| Terminated | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma NCT05618366 | Weill Medical College of Cornell University | Phase 1 |
| Unknown | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL NCT05863845 | Ruijin Hospital | N/A |
| Recruiting | Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study NCT06694779 | Fondazione IRCCS San Gerardo dei Tintori | — |
| Recruiting | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy NCT05757219 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Unknown | Decitabine and Anti-PD-1 in R/R DLBCL NCT05816746 | Chinese PLA General Hospital | Phase 2 |
| Completed | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma NCT06031194 | Ohio State University Comprehensive Cancer Center | — |
| Recruiting | A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Mu NCT06625203 | OWKIN | — |
| Recruiting | Frontline of ASCT in High-risk DLBCL NCT05831865 | Peking University People's Hospital | — |
| Recruiting | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves NCT05512390 | AbbVie | Phase 1 |
| Active Not Recruiting | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic NCT05665062 | Synthekine | Phase 1 |
| Active Not Recruiting | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers NCT05749549 | Shanghai Blueray Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05784987 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Recruiting | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies NCT05618028 | AbbVie | Phase 1 |
| Not Yet Recruiting | Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIM NCT05746858 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Unknown | Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI NCT06290817 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Th NCT05725720 | University of Bologna | — |
| Active Not Recruiting | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma NCT05660967 | Genmab | Phase 2 |
| Unknown | R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma NCT05777369 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Unknown | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma NCT05673447 | Changhai Hospital | EARLY_Phase 1 |
| Withdrawn | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies NCT03999658 | Sorrento Therapeutics, Inc. | Phase 2 |
| Terminated | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05498220 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Unknown | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical NCT05715606 | Anhui Provincial Hospital | EARLY_Phase 1 |
| Active Not Recruiting | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and NCT05578976 | Genmab | Phase 3 |
| Active Not Recruiting | A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL NCT05658562 | Tanabe Pharma Corporation | Phase 1 / Phase 2 |
| Recruiting | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Lar NCT05455697 | University of Washington | Phase 1 / Phase 2 |
| Completed | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and S NCT05694364 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma NCT05256641 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T C NCT05675982 | Centre Henri Becquerel | N/A |
| Recruiting | Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients NCT05809180 | The First Affiliated Hospital of Soochow University | N/A |
| Recruiting | Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy NCT05377307 | Pell Bio-Med Technology Co., Ltd. | — |
| Active Not Recruiting | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Re NCT05429268 | Incyte Corporation | Phase 3 |
| Recruiting | Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma NCT05412290 | Washington University School of Medicine | Phase 1 |
| Withdrawn | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma NCT05934097 | Fate Therapeutics | Phase 1 |
| Recruiting | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL NCT05659628 | Ningbo No. 1 Hospital | Phase 1 |
| Active Not Recruiting | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas NCT05565417 | Immunitas Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression NCT06005870 | Huazhong University of Science and Technology | Phase 2 |
| Terminated | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies NCT05611853 | BioNova Pharmaceuticals (Shanghai) LTD. | Phase 1 / Phase 2 |
| Unknown | Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed NCT05575973 | Jianfeng Zhou | Phase 2 |
| Active Not Recruiting | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B- NCT07226752 | Genmab | Phase 3 |
| Unknown | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients NCT05823701 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327 | Peking Union Medical College Hospital | N/A |
| Active Not Recruiting | RadiothErapy priMIng for CAR-T NCT04726787 | University College, London | N/A |
| Active Not Recruiting | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in NCT05451810 | Genmab | Phase 2 |
| Completed | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. NCT06271369 | Novartis Pharmaceuticals | — |
| Unknown | Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma NCT05189782 | Ruijin Hospital | — |
| Active Not Recruiting | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) NCT05192486 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL NCT05498259 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R- NCT05222555 | Incyte Corporation | Phase 1 / Phase 2 |
| Unknown | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma NCT05444322 | He Huang | EARLY_Phase 1 |
| Not Yet Recruiting | Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma NCT05298293 | Weprom | N/A |
| Active Not Recruiting | Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT05221645 | University of Southampton | Phase 2 |
| Completed | Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse NCT05338892 | Regeneron Pharmaceuticals | — |
| Terminated | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants Wit NCT05144009 | ADC Therapeutics S.A. | Phase 2 |
| Unknown | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse La NCT05428670 | First Affiliated Hospital of Wenzhou Medical University | Phase 2 |
| Completed | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL NCT05233033 | Kymera Therapeutics, Inc. | Phase 1 |
| Recruiting | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354 | Adaptive Biotechnologies | — |
| Recruiting | Genotype-guided Treatment in DLBCL NCT05351346 | Ruijin Hospital | Phase 3 |
| Recruiting | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell NCT05326243 | Pell Bio-Med Technology Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participa NCT05121103 | Epizyme, Inc. | Phase 1 |
| Recruiting | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 NCT05518383 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 |
| Recruiting | Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma NCT05348213 | Ruijin Hospital | Phase 2 |
| Completed | A Retrospective Study on Extranodal DLBCL NCT06549361 | Ruijin Hospital | — |
| Recruiting | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukem NCT05281809 | John Lister | Phase 2 |
| Terminated | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL NCT05265975 | Antengene Corporation | Phase 1 / Phase 2 |
| Unknown | Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL NCT05269914 | The Affiliated Hospital of Qingdao University | N/A |
| Not Yet Recruiting | First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP NCT05280626 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Active Not Recruiting | Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment NCT04978584 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-ce NCT05179733 | Ruijin Hospital | Phase 3 |
| Recruiting | R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse NCT05257018 | Fudan University | Phase 2 |
| Completed | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Of NCT06782854 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Active Not Recruiting | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells NCT04911478 | Adicet Therapeutics | — |
| Unknown | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD3 NCT05208853 | Zhejiang University | EARLY_Phase 1 |
| Completed | Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab NCT04928573 | Libbs Farmacêutica LTDA | — |
| Withdrawn | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesiri NCT04974996 | ADC Therapeutics S.A. | Phase 1 |
| Unknown | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-ce NCT05200312 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Terminated | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutatio NCT05153330 | Biomea Fusion Inc. | Phase 1 |
| Recruiting | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemi NCT06081478 | Beijing Tongren Hospital | Phase 2 |
| Recruiting | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed o NCT05139017 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Unknown | ZR-CHOP in DLBCL With Specific Gene Abnormality NCT05290337 | Fudan University | Phase 2 |
| Recruiting | Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma NCT07443514 | Institute of Oncology Ljubljana | N/A |
| Terminated | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents Wi NCT05179603 | Sanofi | Phase 2 |
| Terminated | Imaging Apoptosis for Lymphoma Treatment Response NCT05048732 | Washington University School of Medicine | EARLY_Phase 1 |
| Completed | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting NCT05108805 | Vanderbilt-Ingram Cancer Center | Phase 4 |
| Suspended | Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma NCT04850495 | Yazeed Sawalha | Phase 1 |
| Active Not Recruiting | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) NCT04546620 | University Hospital Southampton NHS Foundation Trust | Phase 2 |
| Unknown | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL NCT05054426 | Peking Union Medical College Hospital | Phase 3 |
| Unknown | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL NCT05290090 | Zhejiang Cancer Hospital | Phase 2 |
| Terminated | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product NCT05645744 | Mustang Bio | — |
| Recruiting | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in P NCT04981795 | Incyte Corporation | — |
| Unknown | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk NCT05018520 | Ruijin Hospital | Phase 3 |
| Unknown | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma NCT05020392 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies NCT05006716 | BeOne Medicines | Phase 1 / Phase 2 |
| Active Not Recruiting | Copanlisib Plus Venetoclax in R/R DLBCL NCT04572763 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line NCT04670029 | Weprom | Phase 3 |
| Active Not Recruiting | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma NCT04526834 | Tessa Therapeutics | Phase 1 |
| Recruiting | R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden NCT05040555 | oubai, MD/PhD | N/A |
| Active Not Recruiting | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866 | Miltenyi Biomedicine GmbH | Phase 2 |
| Completed | Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data NCT06392763 | Novartis Pharmaceuticals | — |
| Recruiting | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgki NCT04491370 | New York Medical College | Phase 1 / Phase 2 |
| Completed | Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and O NCT05918809 | Novartis Pharmaceuticals | — |
| Recruiting | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745 | Newave Pharmaceutical Inc | Phase 1 |
| Terminated | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS NCT05022797 | Fundacion CRIS de Investigación para Vencer el Cáncer | Phase 2 |
| Recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Rel NCT04739813 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher NCT04914741 | Peter MacCallum Cancer Centre, Australia | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. NCT04604067 | Swiss Cancer Institute | Phase 2 |
| Suspended | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL NCT04855253 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Enrolling By Invitation | Chidamide in Patients With Recurrent and Refractory Diffuse Large b NCT05690191 | Second Affiliated Hospital of Soochow University | — |
| Unknown | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NCT04763083 | NovalGen Ltd. | Phase 1 |
| Active Not Recruiting | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Pat NCT04824092 | Incyte Corporation | Phase 3 |
| Terminated | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma NCT04517435 | Deepa Jagadeesh | Phase 1 / Phase 2 |
| Unknown | Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphom NCT05097443 | Shandong Provincial Hospital | Phase 3 |
| Unknown | A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma NCT04827004 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in Germa NCT07103486 | Novartis Pharmaceuticals | — |
| Recruiting | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy NCT04442412 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients NCT04858568 | University Hospital Southampton NHS Foundation Trust | — |
| Active Not Recruiting | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML NCT04787263 | Bambino Gesù Hospital and Research Institute | Phase 1 / Phase 2 |
| Terminated | A Phase 1 Study of ADI-001 in B Cell Malignancies NCT04735471 | Adicet Therapeutics | Phase 1 |
| Terminated | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies NCT04844086 | Eden BioCell Ltd. | Phase 1 |
| Recruiting | A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma NCT04594642 | AstraZeneca | Phase 1 |
| Unknown | Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin NCT05164770 | Shandong Provincial Hospital | Phase 3 |
| Unknown | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL NCT04502394 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combinat NCT04408638 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Split-Dose R-CHOP for Older Adults With DLBCL NCT03943901 | University of Wisconsin, Madison | Phase 2 |
| Completed | The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma NCT04695366 | Herlev Hospital | — |
| Completed | Single-Cell Map of Immune and Lymphoma Cells in B-cell Non-Hodgkin's Lymphoma NCT04696692 | Institut Claudius Regaud | N/A |
| Recruiting | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With R NCT04512716 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Withdrawn | POLA+BR for Relapsed or Refractory DLBCL NCT04535102 | University of Colorado, Denver | Phase 2 |
| Unknown | A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） NCT04610970 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | CAR T Cell Therapy Related Cardiovascular Outcomes NCT05130489 | University College London Hospitals | — |
| Active Not Recruiting | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Larg NCT04628494 | Genmab | Phase 3 |
| Withdrawn | Diet, Physical Activity and Body Composition Changes During R-CHOP NCT04293900 | George Washington University | — |
| Suspended | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymph NCT04668365 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Part NCT04661007 | Incyte Biosciences Japan GK | Phase 1 / Phase 2 |
| Unknown | Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL NCT04659434 | Qian Wenbin | Phase 2 |
| Withdrawn | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity NCT04503538 | Wake Forest University Health Sciences | N/A |
| Terminated | Study of LUCAR-20S in Patients With R/R NHL NCT04176913 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) NCT04663347 | Genmab | Phase 1 / Phase 2 |
| Unknown | A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymph NCT04624971 | Sun Yat-sen University | — |
| Unknown | Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years NCT04622579 | Guangdong Provincial People's Hospital | Phase 2 |
| Active Not Recruiting | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) NCT04529772 | Acerta Pharma BV | Phase 3 |
| Unknown | Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma NCT04544059 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Terminated | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma NCT04189952 | University of Miami | Phase 2 |
| Completed | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL NCT04555811 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma NCT04545762 | C. Babis Andreadis | Phase 1 |
| Active Not Recruiting | Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell L NCT04460248 | Ruijin Hospital | Phase 2 |
| Active Not Recruiting | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma NCT04479267 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Active Not Recruiting | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL NCT04404283 | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 |
| Active Not Recruiting | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell NCT04542824 | Genmab | Phase 1 / Phase 2 |
| Unknown | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical T NCT04500561 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab NCT04332822 | Nordic Lymphoma Group | Phase 3 |
| Terminated | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma NCT04433182 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Unknown | An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) NCT04486872 | First Affiliated Hospital of Zhejiang University | Phase 1 |
| Unknown | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL NCT04476459 | Huiqiang Huang | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituxi NCT04236141 | Hoffmann-La Roche | Phase 3 |
| Completed | CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma NCT04812691 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 1 |
| Active Not Recruiting | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers NCT04464200 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Enrolling By Invitation | Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL NCT04491721 | Chinese Academy of Medical Sciences | — |
| Unknown | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL NCT04263584 | University Hospital Muenster | Phase 2 |
| Unknown | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymp NCT04381741 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Unknown | Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lym NCT04425824 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies NCT04279405 | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 |
| Active Not Recruiting | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Ly NCT04323956 | Mayo Clinic | Phase 1 |
| Unknown | Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma NCT04432402 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Unknown | the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Di NCT04914143 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Unknown | Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma NCT04423549 | Sun Yat-sen University | — |
| Terminated | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer NCT04254107 | Seagen Inc. | Phase 1 |
| Completed | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor D NCT04231448 | Chipscreen Biosciences, Ltd. | Phase 3 |
| Recruiting | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Recruiting | Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) NCT04300101 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Completed | A Study of ICP-022 in Patients With R/R DLBCL NCT04438005 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Completed | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab NCT04282018 | BeiGene | Phase 1 / Phase 2 |
| Unknown | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma NCT04058470 | Huiqiang Huang | Phase 1 / Phase 2 |
| Terminated | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas NCT04305444 | Zhejiang DTRM Biopharma | Phase 2 |
| Completed | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) NCT04018248 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL NCT04697160 | MorphoSys AG | — |
| Completed | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia NCT04323657 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Completed | Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL NCT04354402 | SymBio Pharmaceuticals | — |
| Terminated | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas NCT04358458 | Genmab | Phase 1 / Phase 2 |
| Completed | Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes NCT04319237 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Completed | A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine NCT04182204 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenei NCT03842696 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Completed | Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel NCT05541328 | Novartis Pharmaceuticals | — |
| Completed | R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma NCT04214626 | Henan Cancer Hospital | Phase 2 |
| Unknown | Secondary Prognostic Index in RefrActory Lymphoma NCT04804865 | Weprom | — |
| Completed | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Ad NCT04134936 | MorphoSys AG | Phase 1 |
| Unknown | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. NCT04023916 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT04026100 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Recruiting | Study of Out of Specification for Tisagenlecleucel NCT04094311 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda NCT03864419 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lympho NCT03984448 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |